JNJ - Emergent's plant implicated in vaccine mix-up had issues cited by FDA in 2020: AP

Emergent BioSolutions ([[EBS]] -12.9%) is trading sharply lower today in reaction to yesterday’s New York Times report over the accidental vaccine contamination at its Baltimore plant manufacturing two coronavirus vaccines developed by Johnson & Johnson ([[JNJ]] -1.1%) and AstraZeneca ([[AZN]] -0.4%).According to Associated Press, Emergent’s Bayview factory where the incident occurred had a series of lapses as pointed out by the FDA during an inspection in April 2020 just as JNJ partnered with Emergent for COVID-19 vaccine production.Among the problems cited by the federal agency included insufficient training of employees in relation to current good manufacturing practices and deficiencies in the testing of a potential treatment for anthrax.Despite 15M of vaccine doses becoming useless, JNJ has however reiterated its commitment to supply 100M doses of COVID-19 shots to the U.S. by H1 2021 with plans to achieve the target by the end of May.The company also said it has delivered 20M vaccine doses to the U.S. by

For further details see:

Emergent’s plant implicated in vaccine mix-up had issues cited by FDA in 2020: AP